NY-ESO-1 (157-165) peptide – SLLMWITQC

HLA-A*02 Major Histocompatibility Complex (MHC) allele

HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA),that are cell surface receptors,presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood,cell death will be initiated via apoptosis.

NY-ESO-1 protein

Peptides presented by MHC class I molecule,are usually between 7 and 11 amino acids,originating from proteins expressed by the cell. SLLMWITQC peptide derives from New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) protein,which is part of a well-characterized group of cancer/testis antigens (CTAs).

Normally,NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas,as well as in many other solid tumors and hematological malignancies.

NY-ESO-1 (157-165) peptide application

Class I HLA molecules of the cancerous cells cited above present peptides from NY-ESO-1 protein,including SLLMWITQC,that binds the binding cleft of the HLA-A*0201 complex. NY-ESO-1 being the most immunogenic among the CTA family members,its peptides constitute attractive targets for specific immunotherapies and the stimulation of human NY-ESO-1 specific CD8⁺ T cells.

NY-ESO-1 (157-165) peptide is used to stimulate specific cytotoxic T-cells in PBMCs and to analyze by ELISPOT peptide epitope,specificity,and cytokine production,like IFN-γ. SLLMWITQC peptide has been used with adjuvant in protein nanoparticles in order to study cell-mediated immune responses and is also used in clinical trial to study the immunological effects of vaccines containing NY-ESO-1 (157-165).

SB-PEPTIDE also offers NY-ESO-1 (157-165) C165V variant peptide,known to have a higher affinity to HLA-A2 molecules.

Technical specifications

Price

References